| Added by | tchardes |
|---|---|
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer |
| Creator | Bourillon et al. |
| Author | Laura Bourillon |
| Author | Céline Bourgier |
| Author | Nadège Gaborit |
| Author | Véronique Garambois |
| Author | Eva Llès |
| Author | Alexandre Zampieri |
| Author | Charline Ogier |
| Author | Marta Jarlier |
| Author | Nina Radosevic-Robin |
| Author | Béatrice Orsetti |
| Author | Hélène Delpech |
| Author | Charles Theillet |
| Author | Pierre-Emmanuel Colombo |
| Author | David Azria |
| Author | André Pèlegrin |
| Author | Christel Larbouret |
| Author | Thierry Chardès |
| Abstract | Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by poor response to chemotherapy and radiotherapy due to the lack of efficient therapeutic tools and early diagnostic markers. We previously generated the nonligand competing anti-HER3 antibody 9F7-F11 that binds to pancreatic tumor cells and induces tumor regression in vivo in experimental models. Here, we asked whether coupling 9F7-F11 with a radiosensitizer, such as monomethylauristatin E (MMAE), by using the antibody-drug conjugate (ADC) technology could improve radiation therapy efficacy in PDAC. We found that the MMAE-based HER3 antibody-drug conjugate (HER3-ADC) was efficiently internalized in tumor cells, increased the fraction of cells arrested in G2/M, which is the most radiosensitive phase of the cell cycle, and promoted programmed cell death of irradiated HER3-positive pancreatic cancer cells (BxPC3 and HPAC cell lines). HER3-ADC decreased the clonogenic survival of irradiated cells by increasing DNA double-strand break formation (based on ?H2AX level), and by modulating DNA damage repair. Tumor radiosensitization with HER3-ADC favored the inhibition of the AKT-induced survival pathway, together with more efficient caspase 3/PARP-mediated apoptosis. Incubation with HER3-ADC before irradiation synergistically reduced the phosphorylation of STAT3, which is involved in chemoradiation resistance. In vivo, the combination of HER3-ADC with radiation therapy increased the overall survival of mice harboring BxPC3, HPAC cell xenografts or patient-derived xenografts, and reduced proliferation (KI67-positive cells). Combining auristatin radiosensitizer delivery via an HER3-ADC with radiotherapy is a new promising therapeutic strategy in PDAC. |
| Publication | International Journal of Cancer |
| Volume | 145 |
| Issue | 7 |
| Pages | 1838-1851 |
| Date | 2019-10-01 |
| Journal Abbr | Int J Cancer |
| Language | eng |
| DOI | 10.1002/ijc.32273 |
| ISSN | 1097-0215 |
| Library Catalog | PubMed |
| Extra | PMID: 30882895 |
| Tags | ADC, Animals, Antibodies, Monoclonal, Murine-Derived, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Cell Proliferation, Cell Survival, Chemoradiotherapy, cnrs, corresponding, HER3/ErbB3, Humans, Immunoconjugates, Immunologic Factors, irradiation, last, mabimprove, Mice, monomethylauristatin, Oligopeptides, original, Pancreatic Neoplasms, Phosphorylation, STAT3 Transcription Factor, Treatment Outcome, Xenograft Model Antitumor Assays |
| Date Added | 2021/03/19 - 17:06:24 |
| Date Modified | 2023/12/15 - 15:09:43 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
